Clinical trials: Ranibizumab
Glaucoma
Ranibizumab in Preventing Failure of Ahmed Valve Glaucoma Surgery
To determine whether ranibizumab therapy before and after tube insertion for glaucoma surgeries can maintain the patency of the tube and prevent scar formation, and increase the chances for a successful procedure compared to…
- Trial name
- NCT00644280
- Testing
- Ranibizumab
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of California, San Francisco
Diabetic Macular Edema
Clinical Study to Evaluate PRO-169 for Diabetic Macular Edema
Phase III clinical study to evaluate the efficacy, expressed as improvement in visual acuity in patients suffering diabetic macular edema after one year of treatment with PRO-169, compared to treatment with Lucentis®…
- Trial name
- PRO-169 (NCT05217680)
- Testing
- Bevacizumab, Lucentis®
- Where
- Mexico
- Volunteers
- 509 people
- Sponsor
- Laboratorios Sophia S.A de C.V.
Neovascular Age-related Macular Degeneration
Study to Compare Efficacy, Safety, and Immunogenicity of LUBT010 (Proposed Ranibizumab Biosimilar) and Lucentis® in Patients With Neovascular AMD
This study is designed to compare the efficacy, safety and immunogenicity of LUBT010 with Lucentis® given as once monthly intravitreal injection in patients with neovascular age-related macular degeneration (AMD).
- Trial name
- NCT04690556
- Testing
- LUBT010 (proposed ranibizumab biosimilar), Lucentis (ranibizumab)
- Where
- 78 sites in United States, Bulgaria and 5 more
- Volunteers
- 600 people
- Sponsor
- Lupin Ltd.
AMD, Wet AMD
INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD
The purpose of this study is to confirm the safety and establish the effectiveness of two doses from the IRay System for the treatment of wet AMD.
- Conditions
- AMD, Wet AMD, Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration
- Trial name
- INTREPID (NCT01016873)
- Testing
- IRay
- Where
- 21 sites in Austria, Czechia and 3 more
- Volunteers
- 230 people
- Sponsor
- Oraya Therapeutics, Inc.
Glaucoma, Rubeosis Iridis
Intravitreal Aflibercept or Ranibizumab for Rubeosis Iridis
Aflibercept (Eylea®) and ranibizumab (Lucentis®) are an anti-VEGF, but there are differences between the two drugs. To determine and compare whether intraocular aflibercept and ranibizumab decreases rubeosis iridis (RI) in…
- Trial name
- NCT02641457
- Testing
- Aflibercept, Ranibizumab
- Where
- Brazil
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Instituto de Olhos de Goiania
Wet Macular Degeneration
Pilot Study of Ranibizumab With and Without Ketorolac Eyedrops for Exudative Age-related Macular Degeneration
The addition of an anti-inflammatory agent could be a valid option for controlling choroidal neovascularization, as simply inhibiting VEGF addresses neither the multifactorial pathogenesis of choroidal neovascularization nor the…
- Trial name
- NCT02060604
- Testing
- Ketorolac + Ranibizumab, Ranibizumab
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Università degli Studi di Brescia
Central Retinal Vein Occlusion
Retinal Blood Flow in Response to an Intravitreal Injection of Ranibizumab for Central Retinal Vein Occlusion (CRVO)
Ranibizumab (Lucentis, Genentech) is an off-label drug used for the clinical treatment of central retinal vein occlusion, which is one of the most common retinal vascular disorders.
- Trial name
- NCT01303276
- Where
- Canada
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Toronto
Choroidal Neovascularization, Diabetic Retinopathy
PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME)
This is a two-part study. The first part (Stratum I) is an open-label, dose escalation, safety, tolerability and pharmacokinetic study, where active study drug (PF-04523655) will be given to all patients who participate.
- Conditions
- Choroidal Neovascularization, Diabetic Retinopathy, Diabetic Macular Edema
- Trial name
- MATISSE (NCT01445899)
- Testing
- PF-04523655 (Stratum I), ranibizumab, PF-04523655 (Stratum II)
- Where
- 51 sites in United States, Belgium and 5 more
- Volunteers
- 258 people
- Sponsor
- Quark Pharmaceuticals
Age Related Macular Degeneration
Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial
The purpose of the study is to evaluate the relative efficacy and safety of treatment of neovascular AMD with Lucentis on a fixed schedule, Avastin on a fixed schedule, Lucentis on a variable schedule, and Avastin on a variable…
- Trial name
- NCT00593450
- Testing
- ranibizumab, bevacizumab
- Where
- 59 sites in United States
- Volunteers
- 1,208 people
- Sponsor
- University of Pennsylvania
Nonarteritic Anterior Ischemic Optic Neuropathy
Ranibizumab Therapy for Non-arteritic Ischemic Optic Neuropathy
The purpose of this study is to explore the safety and efficacy of ranibizumab to treat non-arteritic ischemic optic neuropathy based on clinical and anatomical findings.
- Trial name
- NAION (NCT00561834)
- Testing
- ranibizumab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Colorado, Denver
Diabetic Macular Edema, Diabetic Retinopathy
Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema
PURPOSE: To evaluate the efficacy of switching from bevacizumab to ranibizumab (Lucentis; Genentech, South San Francisco, CA) or aflibercept (Eylea; Regeneron, Tarrytown, NY) in eyes with diabetic macular edema (DME) nonresponders…
- Trial name
- SWITCH (NCT04018833)
- Testing
- Ranibizumab 0.5 MG/0.05 ML Intraocular Solution [LUCENTIS], Aflibercept 40 MG/ML Intraocular Solution [EYLEA]
- Volunteers
- 40 people
- Sponsor
- Bernardete Pessoa MD
Diabetic Retinopathy, Vitreous Hemorrhage
Use of Intravitreal Ranibizumab in the Treatment of Vitreous Hemorrhage
Primary Objective: To investigate the effectiveness of intravitreal applications of 0.5 mg Lucentis (ranibizumab) in patients with vitreous hemorrhage due to proliferative diabetic retinopathy.
- Trial name
- NCT01824043
- Testing
- intravitreal ranibizumab injections
- Where
- Brazil
- Volunteers
- 20 people
- Sponsor
- Hospital Regional de São José - Dr. Homero de Miranda Gomes
Age-related Macular Degeneration
A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration (HARBOR)
This is a Phase III, multicenter, randomized, double-masked, dose-comparison study of the efficacy and safety of ranibizumab injection administered intravitreally to patients with choroidal neovascularization (CNV) secondary to…
- Trial name
- HARBOR (NCT00891735)
- Testing
- Ranibizumab
- Where
- 99 sites in United States
- Volunteers
- 1,097 people
- Sponsor
- Genentech, Inc.
Diabetic Macular Edema
MIcrodoses of raNIbizumab in Diabetic MAcular Edema (MINIMA-2)
The objective of this study is to investigate if the drug ranibizumab administrated by microdose injection into the eye is safe and effective to treat diabetic macular edema.
- Trial name
- MINIMA-2 (NCT01112085)
- Testing
- Ranibizumab 0.05mg, Ranibizumab 0.5mg
- Where
- 6 sites in Argentina, Mexico
- Volunteers
- 72 people
- Sponsor
- Especialistas en Retina Medica y Quirurgica Grupo de Investigacion
Branch Retinal Vein Occlusion
Evaluation of the Usefulness of a PRN Regimen Using Ranibizumab for Macular Edema Due to Branch Retinal Vein Occlusion
Monthly intravitreal ranibizumab (IVR) during the first 6 month had great effect for macular edema with branch retinal vein occlusion (BVO) both in visual and anatomical outcome.
- Trial name
- NCT02478515
- Testing
- Ranibizumab
- Where
- Japan
- Volunteers
- 27 people
- Sponsor
- Nagoya City University
Diabetic Macular Edema
Laser (Selective Retina Therapy) and Drug Combined Intervention in Clinically Significant Diabetic Macular Edema
The objective of this clinical trial is to compare and evaluate the safety and efficacy of Ranibizumab (Lucentis®; Novartis AG, Basel, Switzerland) monotherapy and Ranibizumab combined with R:GEN (Selective Retina Therapy) in…
- Trial name
- NCT03759860
- Testing
- R:GEN laser treatment (Selective Retina Therapy) and Lucentis (ranibizumab) combination therapy
- Where
- South Korea
- Volunteers
- 12 people
- Sponsor
- CynosureLutronic
Age-related Macular Degeneration, Coronary Artery Disease
Ranibizumab and the Risk of Arterial Thromboembolic Events
The investigators assume that ranibizumab might be dangerous in patients with history of coronary artery disease or cerebrovascular events.
- Conditions
- Age-related Macular Degeneration, Coronary Artery Disease, Cerebrovascular Disorders
- Trial name
- RATE (NCT01319188)
- Testing
- 0.5 mg of ranibizumab, 0.5 mg of ranibizumab + photodynamic therapy
- Where
- 2 sites in Netherlands, Russia
- Volunteers
- 380 people, healthy volunteers welcome
- Sponsor
- Ural State Medical University
Macular Edema, Branch Retinal Vein Occlusion
REtinal Vein OccLUsion Treatment With Scatter Laser Guided by UWFA in combiNAtion With Ranibizumab Study
Branch retinal vein occlusion is a leading cause of vision loss. Treatment with ranibizumab (vascular endothelial growth factor (VEGF) inhibitor) on a monthly basis has been associated with improved vision results.
- Trial name
- Revolution (NCT01247220)
- Testing
- Ranibizumab, Peripheral Laser
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Retina Associates of Florida, P.A.
Macular Degeneration, Choroidal Neovascularization
Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)
This study will evaluate the effect of combination therapy with verteporfin photodynamic therapy and ranibizumab on visual acuity compared to ranibizumab monotherapy and the durability of response observed in patients with…
- Trial name
- NCT00433017
- Testing
- Verteporfin Photodynamic Therapy, Ranibizumab
- Where
- 12 sites in Austria, Belgium and 10 more
- Volunteers
- 255 people
- Sponsor
- Novartis
Diabetic Retinopathy, Retinal Diseases
Intravitreal Ranibizumab Combined With Panretinal Photocoagulation in Patients With Proliferative Diabetic Retinopathy
To evaluate the efficacy of combination therapy with ranibizumab (RBZ) and panretinal photocoagulation (PRP) versus PRP alone in patients with treatment-naive bilateral proliferative diabetic retinopathy (PDR) as measured by mean…
- Conditions
- Diabetic Retinopathy, Retinal Diseases, Eye Diseases, Diabetic Angiopathies
- Trial name
- NCT01746563
- Testing
- Ranibizumab, Laser therapy
- Where
- Brazil
- Volunteers
- 30 people
- Sponsor
- University of Sao Paulo